natgillin/translations-raw huggingface dataset:
At week 12, there was a statistically significant improvement in the SPARCC (Spondyloarthritis Research Consortium of Canada) score for the sacroiliac joint (SIJ) as measured by MRI for patients receiving LIFMIOR. 
Pri bolnikih, ki so prejemali zdravilo LIFMIOR, je po 12 tednih prišlo do statistično pomembnega izboljšanja rezultata SPARCC (SPARCC - Spondyloarthritis Research Consortium of Canada; Kanadski konzorcij za raziskovanje spondilartritisa) za sakroiliakalni sklep (SIJ - Sacroiliac Joint), ki so ga merili z magnetnoresonančnim slikanjem.
However, your doctor may determine an alternative frequency at which to inject LIFMIOR. 
Zdravnik vam lahko predpiše tudi drugačno pogostnost injiciranja zdravila LIFMIOR.
Uncommon ≥ 1/1,000 to < 1/100 
Pogosti ≥ 1/100 do < 1/10
Instructions for preparing and giving an injection of LIFMIOR (See overleaf) 
Navodila za pripravo in dajanje injekcije zdravila LIFMIOR (glejte drugo stran navodila)
There is generally no applicable use of LIFMIOR in children aged below 6 years in the indication plaque psoriasis. 
Zdravila LIFMIOR se običajno ne uporablja za zdravljenje psoriaze v plakih pri otrocih, mlajših od 6 let.
Autoimmune hepatitis* 
avtoimunski hepatitis*
Patients also had plaque psoriasis with a qualifying target lesion ≥ 2 cm in diameter. 
Bolniki so imeli tudi psoriazo v plakih, pri čemer so za mejno velikost lezij šteli tiste z ≥ 2 cm premera.
• Infections/surgery: If the child develops a new infection, or is about to have any major surgery, the doctor may wish to monitor the child's treatment with LIFMIOR. 
Okužbe/operacije: Če se pri otroku pojavi nova okužba ali če je pri otroku predvidena kakršnakoli večja operacija, bo zdravnik morda želel spremljati zdravljenje z zdravilom LIFMIOR.
Patients with paediatric plaque psoriasis (aged 4 to 17 years) were administered 0.8 mg/kg (up to a maximum dose of 50 mg per week) of etanercept once weekly for up to 48 weeks. 
Bolniki z otroško psoriazo v plakih (stari od 4 do 17 let) so prejemali po 0,8 mg/kg (do največjega odmerka 50 mg na teden) etanercepta enkrat na teden do 48 tednov.
The 10 mg vial is for children prescribed a dose of 10 mg or less. 
10 mg viala je namenjena za uporabo pri otrocih s predpisanim odmerkom 10 mg ali manj.
A higher rate of major birth defects was observed in one observational study comparing pregnancies exposed to etanercept (n=370) during the first trimester with pregnancies not exposed to etanercept or other TNF-antagonists (n=164) (adjusted odds ratio 2.4, 95% CI: 1.0-5.5). 
V 1 opazovalni študiji, kjer so primerjali nosečnosti, izpostavljene etanerceptu (n = 370) v prvem trimesečju, z nosečnostmi, ki niso bile izpostavljene etanerceptu ali drugim antagonistom TNF (n = 164), so opazili večji delež resnih prirojenih napak (prilagojeno razmerje obetov 2,4, 95 % IZ: 1,0-5,5).
Some patients have developed a reaction at an injection site that was used before. 
Pri nekaterih bolnikih se je reakcija pojavila na mestu predhodnega injiciranja.
• Signs of inflammation of the blood vessels such as pain, fever, redness or warmth of the skin, or itching. 
• znaki vnetja krvnih žil, kot so bolečina, vročina, rdečina ali toplina kože ali srbenje.
Concurrent administration of LIFMIOR and anakinra has been associated with an increased risk of serious infections and neutropenia compared to LIFMIOR alone. 
Sočasna uporaba zdravila LIFMIOR in anakinre je bila povezana s povečanim tveganjem za pojav resnih okužb in nevtropenije v primerjavi z zdravljenjem samo z zdravilom LIFMIOR.
• Then, slowly pull the plunger back to draw the liquid into the syringe (see Diagram 11). 
Nato počasi potegnite bat nazaj, da izvlečete raztopino v brizgo (glejte sliko 11).
Your doctor may decide to continue to monitor the child for the presence of infections after the child stops using LIFMIOR. 
Vaš zdravnik se bo morda odločil, da bo otroka tudi po koncu zdravljenja z zdravilom LIFMIOR spremljal glede prisotnosti okužb.
• Infections/diabetes: Tell your doctor if you or the child have a history of recurrent infections or suffer from diabetes or other conditions that increase the risk of infection. 
Okužbe/sladkorna bolezen: Povejte zdravniku, če imate vi ali otrok ponavljajoče se okužbe, sladkorno bolezen ali kakšno drugo stanje, pri katerem je tveganje za okužbo večje.
Treatment should be discontinued in patients who show no response after 12 weeks. 
Pri bolnikih, ki po 12 tednih ne pokažejo odziva, je treba zdravljenje prekiniti.
48 alcohol swabs 
48 alkoholnih blazinic
For psoriasis in patients from the age of 6 years, the usual dose is 0.8 mg of LIFMIOR per kg bodyweight (up to a maximum of 50 mg), and should be given once weekly. 
Za psoriazo pri bolnikih od 6. leta starosti naprej je običajni odmerek 0,8 mg zdravila LIFMIOR na kg telesne mase (do največ 50 mg), dajati pa ga je treba enkrat na teden.
Neurological disorders 
Nevrološke bolezni
• Infections/diabetes: Tell your doctor if the child has a history of recurrent infections, or suffers from diabetes or other conditions that increase the risk of infection. 
Okužbe/sladkorna bolezen: Povejte zdravniku, če ima otrok ponavljajoče se okužbe, sladkorno bolezen ali kako drugo stanje, pri katerem je tveganje za okužbo večje.
• Nervous system and eye disorders: Tell your doctor if the child has multiple sclerosis, optic neuritis (inflammation of the nerves of the eyes) or transverse myelitis (inflammation of the spinal cord). 
Bolezni živčevja in očesne bolezni: Povejte zdravniku, če ima otrok multiplo sklerozo, optični nevritis (vnetje očesnega živca) ali transverzni mielitis (vnetje hrbtnega mozga).
In part 1, all patients received 0.4 mg/kg (maximum 25 mg per dose) LIFMIOR subcutaneously twice weekly. 
V prvem delu študije so vsi bolniki 2-krat tedensko prejemali po 0,4 mg/kg (največ 25 mg na odmerek) zdravila LIFMIOR subkutano.
Common ≥ 1/100 to 
Pogosti ≥ 1/100 do
• While holding the needle and container in one hand, pick up the syringe and insert the syringe tip into the needle opening. 
Medtem ko držite iglo z neodstranjenim delom embalaže v eni roki, z drugo roko primite brizgo ter vstavite konico brizge v odprtino igle.
• Nervous system and eye disorders: Tell your doctor if you or the child have multiple sclerosis, optic neuritis (inflammation of the nerves of the eyes) or transverse myelitis (inflammation of the spinal cord). 
Bolezni živčevja in očesne bolezni: Povejte zdravniku, če imate vi ali otrok multiplo sklerozo, optični nevritis (vnetje očesnega živca) ali transverzni mielitis (vnetje hrbtnega mozga).
Adult patients with ankylosing spondylitis 
Odrasli bolniki z ankilozirajočim spondilitisom
In an open-label, single-dose, two-treatment, crossover study in healthy volunteers, etanercept administered as a single 50 mg/ml injection was found to be bioequivalent to two simultaneous injections of 25 mg/ml. 
V odprti, enoodmerni, navzkrižni študiji pri zdravih prostovoljcih z dvema oblikama zdravljenja so ugotovili, da je enkratna injekcija 50 mg/ml etanercepta bioekvivalentna dvema sočasnima injekcijama 25 mg/ml.
Although there is elimination of radioactivity in urine after administration of radiolabelled etanercept to patients and volunteers, increased etanercept concentrations were not observed in patients with acute renal failure. 
Pri bolnikih in zdravih prostovoljcih se po uporabi z radioaktivnim izotopom označenega etanercepta le-ta izloča z urinom, vendar pa pri bolnikih z akutno odpovedjo ledvic niso zaznali povečanih koncentracij etanercepta.
You can press a cotton ball or gauze over the injection site for 10 seconds. 
Na mesto injiciranja lahko za 10 sekund pritisnete kos vate ali gazo.
Overall, infections were more commonly reported in patients treated with etanercept compared to methotrexate alone (3.8 versus 2%), and the infections associated with etanercept use were of a more severe nature. 
Na splošno so pri bolnikih, ki so se zdravili z etanerceptom, pogosteje poročali o okužbah kot pri bolnikih, ki so se zdravili samo z metotreksatom (3,8 % v primerjavi z 2 %).
Rare ≥ 1/10,000 to 
Redki ≥ 1/10.000 do
Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. 
Zdravljenje hudega aktivnega ankilozirajočega spondilitisa pri odraslih, če je bil odziv na konvencionalno zdravljenje nezadosten.
Cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, lupus-like syndrome 
Bolezni mišičnoskeletnega sistema in vezivnega tkiva kožni eritematozni lupus, subakutni kožni eritematozni lupus, lupusu podoben sindrom
In an open-label, safety extension study, 58 paediatric patients from the above study (from the age of 4 years at time of enrolment) continued to receive LIFMIOR for up to 10 years. 
Varnost uporabe zdravila so spremljali v odprtem podaljšku študije, v katerem se je 58 otrok iz zgoraj omenjene študije (v času vključitve so bili stari 4 leta ali več) z zdravilom LIFMIOR zdravilo do 10 let.
LIFMIOR is supplied as a solution for injection in a pre-filled pen (MYCLIC) (solution for injection). 
Zdravilo LIFMIOR je na voljo kot raztopina za injiciranje v napolnjenem injekcijskem peresniku (MYCLIC) (raztopina za injiciranje).
Patients in this study received a dose of 50 mg LIFMIOR or placebo once weekly for 12 weeks and then all patients received open-label 50 mg LIFMIOR once weekly for an additional 12 weeks. 
Bolniki v tej študiji so dobivali odmerek 50 mg zdravila LIFMIOR ali placebo enkrat na teden 12 tednov, potem pa so vsi bolniki v odprtem delu dobivali 50 mg zdravila LIFMIOR enkrat na teden dodatnih 12 tednov.
Uveitis, scleritis 
Očesne bolezni uveitis, skleritis
Various malignancies have also been reported with use of LIFMIOR, including cancers of the breast, lung, skin and lymph glands (lymphoma). 
Pri uporabi zdravila LIFMIOR so poročali tudi o pojavu različnih malignih obolenj, vključno z rakom dojke, pljuč, kože in bezgavk (limfom).
Caution should be exercised in patients being treated with LIFMIOR who have a previous history of blood dyscrasias. 
Previdnost je potrebna pri bolnikih, zdravljenih z zdravilom LIFMIOR, ki imajo krvno diskrazijo v anamnezi.
Push the plunger all the way into the syringe (see Diagram 10). 
Bat brizge potisnite do konca v brizgo (glejte sliko 10).
Powder and solvent for solution for injection (powder for injection). 
prašek in vehikel za raztopino za injiciranje (prašek za injekcijo)
• Anti-diabetic medicines: Tell your doctor if the child has diabetes or is taking medicines to treat diabetes. 
Zdravila za zdravljenje sladkorne bolezni: Povejte zdravniku, če ima otrok sladkorno bolezen ali če jemlje zdravila za zdravljenje sladkorne bolezni.
If you are concerned with the appearance of the solution, then contact your pharmacist for assistance. 
Če vas skrbi izgled raztopine, se posvetujte s farmacevtom.
Do not attempt to recap the pen. 
Na peresnik ne poskušajte znova namestiti pokrovčka.
• Inflammatory bowel disease (IBD): There have been cases of IBD in patients with juvenile idiopathic arthritis (JIA) treated with LIFMIOR. 
• Kronična vnetna črevesna bolezen (KVČB): Pri bolnikih z juvenilnim idiopatskim artritisom (JIA), ki so se zdravili z zdravilom LIFMIOR, so poročali o primerih KVČB.
The possibility exists for TNF-antagonists, including LIFMIOR, to affect host defences against infections and malignancies since TNF mediates inflammation and modulates cellular immune responses. 
Za antagoniste TNF, vključno z zdravilom LIFMIOR, velja, da lahko vplivajo na naravno odpornost bolnika proti okužbam in malignim obolenjem, saj TNF sodeluje pri vnetju in uravnava celični imunski odziv.
Axial spondyloarthritis 
Aksialni spondilartritis
If these signs occur, tell your doctor immediately, or visit the casualty department at your nearest hospital. 
Če se ti znaki pojavijo, se nemudoma posvetujte z zdravnikom ali pojdite v ambulanto za nujno pomoč najbližje bolnišnice.
Doses of 25 mg of LIFMIOR (based on dose-finding studies in patients with rheumatoid arthritis) or placebo were administered SC twice a week for 6 months. 
Odmerke zdravila LIFMIOR po 25 mg (na podlagi študij za ugotovitev odmerkov pri bolnikih z revmatoidnim artritisom) ali placebo so dajali subkutano dvakrat na teden 6 mesecev.
Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA) (see section 5.1). 
Zdravljenje zmerne do hude psoriaze v plakih pri odraslih, ki se ne odzovejo na drugo sistemsko zdravljenje, vključno s ciklosporinom, metotreksatom ali psoralenom in ultravijolično svetlobo UV-A (PUVA), oziroma je pri njih le-to kontraindicirano ali ga ne prenašajo (glejte poglavje 5.1).
Histiocytosis haematophagic (macrophage activation 
hematofagna histiocitoza (sindrom aktivacije makrofagov)
Other presentations of LIFMIOR are available in strengths of 10 mg, 25 mg and 50 mg. 
Druge oblike zdravila LIFMIOR so na voljo v jakostih 10 mg, 25 mg in 50 mg.
• Hepatitis C: Tell your doctor if the child has hepatitis C. Your doctor may wish to monitor the treatment with LIFMIOR in case the infection worsens. 
.• Hepatitis C: Povejte zdravniku, če ima vaš otrok hepatitis C. Zdravnik bo morda želel spremljati zdravljenje z zdravilom LIFMIOR za primer, če bi se okužba poslabšala.
There have been postmarketing reports of worsening of CHF, with and without identifiable precipitating factors, in patients taking LIFMIOR. 
Obstajajo poročila iz obdobja trženja o poslabšanju KSP pri bolnikih, ki jemljejo zdravilo LIFMIOR, ob prisotnosti dejavnikov, ki bi lahko sprožili tako poslabšanje, in brez njih.
Your doctor may decide if you or the child need less anti-diabetic medicine while taking LIFMIOR. 
Zdravnik lahko odloči, da boste vi ali otrok med jemanjem zdravila LIFMIOR potrebovali manj zdravila za zdravljenje sladkorne bolezni.
There is generally no applicable use of LIFMIOR in children aged below 2 years in the indication juvenile idiopathic arthritis. 
Zdravila LIFMIOR se običajno ne uporablja za zdravljenje juvenilnega idiopatskega artritisa pri otrocih, mlajših od 2 let.
• Infections/surgery: If you or the child develop a new infection, or are about to have any major surgery, your doctor may wish to monitor the treatment with LIFMIOR. 
Okužbe/operacije: Če se pri vas ali otroku pojavi nova okužba ali če je pri vas ali otroku predvidena kakršnakoli večja operacija, bo zdravnik morda želel spremljati zdravljenje z zdravilom LIFMIOR.
Side effects in children and adolescents 
Neželeni učinki pri otrocih in mladostnikih
Do not attempt to administer an injection until you are sure that you understand how to use the MYCLIC pen properly. 
Dokler niste povsem prepričani, da razumete, kako je treba pravilno uporabljati peresnik MYCLIC, ne poskušajte injicirati zdravila.
16 alcohol swabs 
16 alkoholnih blazinic
The syringe inside the pen is made from clear type 1 glass with a stainless steel 27 gauge needle, rubber needle cover, and plastic plunger. 
Injekcijska brizga v peresniku je izdelana iz prozornega stekla tipa I z iglo velikosti 27 iz nerjavečega jekla, gumijastim pokrovčkom igle in plastičnim batom.
The three recommended injection sites for LIFMIOR using a pre-filled syringe include: (1) the front of the middle thighs; (2) the abdomen, except for the 5 cm area right around the navel; and (3) the outer area of the upper arms (see Diagram 1). 
Za injiciranje napolnjene injekcijske brizge zdravila LIFMIOR so priporočljiva tri injekcijska mesta: (1) na sredini sprednjega dela stegna; (2) na trebuhu, razen v predelu 5 cm okrog popka; in (3) na zunanjem delu nadlakti (glejte sliko 1).
Step 3: Injecting the LIFMIOR solution 
Korak 3: Injiciranje raztopine zdravila LIFMIOR
Pruritus, rash Angioedema, psoriasis (including new onset or worsening and pustular, primarily palms and soles), urticaria, psoriasiform rash 
Bolezni kože in podkožja pruritus, izpuščaj angioedem, psoriaza (vključno s tako, ki se začne na novo ali se poslabša, in pustularno, predvsem na dlaneh in podplatih), urtikarija, psoriaziformen izpuščaj
Among patients receiving LIFMIOR, the clinical responses generally appeared within 1 to 2 weeks after initiation of therapy and nearly always occurred by 3 months. 
Pri bolnikih na zdravilu LIFMIOR se je klinični odziv običajno pojavil že v prvem ali drugem tednu zdravljenja, skoraj vedno pa je nastopil do 3. meseca.
Solution for injection in a pre-filled pen (MYCLIC) 
raztopina za injiciranje v napolnjenem injekcijskem peresniku (MYCLIC)
Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. 
Zdravljenje hude kronične psoriaze v plakih pri otrocih in mladostnikih od 6. leta starosti naprej, pri katerih se z drugo sistemsko terapijo ali fototerapijo bolezni ne da zadostno obvladati ali jih bolniki ne prenašajo.
This injection should not be mixed in the same syringe or vial with any other medicine. 
Tega zdravila ne smete mešati z drugimi zdravili v isti injekcijski brizgi ali viali.
Additionally, some patients developed recall injection site reactions characterised by a skin reaction at the most recent site of injection, along with the simultaneous appearance of injection site reactions at previous injection sites. 
Poleg tega so nekateri bolniki dobili tako imenovano spominsko lokalno reakcijo na mestu injiciranja; ob naslednjem injiciranju se je poleg reakcije na tedanjem mestu injiciranja sočasno pojavila reakcija tudi na prejšnjih mestih injiciranja.
The safety and efficacy of 50 mg LIFMIOR (two 25 mg SC injections) administered once weekly were evaluated in a double-blind, placebo-controlled study of 420 patients with active RA. 
Varnost in učinkovitost 50 mg zdravila LIFMIOR (dve subkutani injekciji po 25 mg) enkrat na teden so ocenili v dvojno slepi, s placebom nadzorovani študiji pri 420 bolnikih z aktivnim revmatoidnim artritisom.
*Some patients did not provide complete data for each endpoint **ASAS=Assessments in Spondyloarthritis International Society ***Bath Ankylosing Spondylitis Disease Activity Index a: p <0.001, b:<0.01 and c:<0.05, respectively between LIFMIOR and placebo 
** ASAS = Mednarodno združenje za ocenjevanje spondilartritisa *** Indeks Bath za ocenjevanje aktivnosti ankilizirajočega spondilitisa a: p < 0,001, b: < 0,01 oziroma c: < 0,05 med zdravilom LIFMIOR in placebom
When reconstituted, the solution contains 10 mg/ml of etanercept. 
Po rekonstituciji raztopina vsebuje 10 mg/ml etanercepta.
ACR 50 Month 3 
ACR 50 3. mesec 6. mesec
The active ingredient in LIFMIOR is etanercept. 
Učinkovina zdravila LIFMIOR je etanercept.
• The three recommended injection sites for LIFMIOR include: (1) the front of the middle thighs; (2) the abdomen, except for the 5 cm area right around the navel; and (3) the outer area of the upper arms (see Diagram 17). 
Za injiciranje zdravila LIFMIOR so priporočljiva tri injekcijska mesta: (1) na sredini sprednjega dela stegna; (2) na trebuhu, razen v predelu 5 cm okrog popka; in (3) na zunanjem delu nadlakti (glejte sliko 17).
Step 1: Setting up for an injection 
Korak 1: Priprava na injiciranje
Adult patients with psoriatic arthritis 
Odrasli bolniki s psoriatičnim artritisom
Study 2 
Študija 2
This injection should not be mixed with any other medicine. 
Tega zdravila ne smete mešati z drugimi zdravili.
However, any of the above symptoms may indicate an allergic reaction to LIFMIOR, so you should seek immediate medical attention. 
Resne alergijske reakcije so redke, vendar pa lahko katerikoli od zgoraj navedenih simptomov kaže na pojav alergijske reakcije na zdravilo LIFMIOR, zato morate nemudoma poiskati zdravniško pomoč.
Your doctor will determine if LIFMIOR is an appropriate treatment. 
Zdravnik bo presodil o primernosti zdravljenja z zdravilom LIFMIOR.
The dose should be 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly. 
Odmerek naj bo 0,8 mg/kg (do največ 50 mg na odmerek) enkrat na teden.
Step 1: Preparing for an LIFMIOR injection 
Korak 1: Priprava na injiciranje zdravila LIFMIOR
The efficacy of LIFMIOR was compared to methotrexate in a randomised, active-controlled study with blinded radiographic evaluations as a primary endpoint in 632 adult patients with active rheumatoid arthritis (<3 years duration) who had never received treatment with methotrexate. 
V randomizirani študiji, nadzorovani z učinkovino, so s slepo radiografsko oceno kot primarnim opazovanim dogodkom primerjali učinkovitost zdravila LIFMIOR z učinkovitostjo metotreksata pri 632 odraslih bolnikih z aktivnim revmatoidnim artritisom (trajanje bolezni manj kot 3 leta), ki se pred tem nikoli niso zdravili z metotreksatom.
At 24 weeks, 56% of patients in the LIFMIOR-treated group had achieved the PASI 75 compared to 5% of placebo-treated patients. 
V 24. tednu je 56 % bolnikov doseglo PASI 75 v skupini, zdravljeni z zdravilom LIFMIOR, v skupini s placebom pa 5 % bolnikov.
Your doctor may decide to continue to monitor you or the child for the presence of infections after you or the child stop using LIFMIOR. 
Vaš zdravnik se bo morda odločil, da bo vas ali vašega otroka tudi po koncu zdravljenja z zdravilom LIFMIOR spremljal glede prisotnosti okužb.
LIFMIOR may be stored at temperatures up to a maximum of 25° C for a single period of up to four weeks; after which, it should not be refrigerated again. 
Zdravilo LIFMIOR se lahko shranjuje pri temperaturi do največ 25 °C za enkratno obdobje do štirih tednov, po katerem se ga ne sme več ohladiti.
Severe adverse events reported included varicella with signs and symptoms of aseptic meningitis, which resolved without sequelae (see also section 4.4), appendicitis, gastroenteritis, depression/personality disorder, cutaneous ulcer, oesophagitis/gastritis, group A streptococcal septic shock, type I diabetes mellitus, and soft tissue and post-operative wound infection. 
Hudi neželeni učinki, o katerih so poročali, so bili: norice z znaki in simptomi aseptičnega meningitisa, ki je izzvenel brez posledic (glejte tudi poglavje 4.4), vnetje slepiča, gastroenteritis, depresija/osebnostne motnje, kožne razjede, ezofagitis/gastritis, streptokokni septični šok (streptokoki skupine A), sladkorna bolezen tipa I in okužbe mehkih tkiv ter postoperativnih ran.
• Latex: The needle cover is made from latex (dry natural rubber). 
Lateks: Pokrovček igle je izdelan iz lateksa (suhega naravnega kavčuka).
Before injection, LIFMIOR single-use pre-filled syringe should be allowed to reach room temperature (approximately 15 to 30 minutes). 
Pred injiciranjem je treba napolnjene injekcijske peresnike zdravila LIFMIOR za enkratno uporabo segreti na sobno temperaturo (počakati približno 15 do 30 minut).
24 pre-filled syringes 24 alcohol swabs 
24 napolnjenih injekcijskih brizg 24 alkoholnih blazinic
• Cancer: Tell your doctor if you have or have ever had lymphoma (a type of blood cancer) or any other cancer before you are given LIFMIOR. 
Rak: Preden boste prejeli zdravilo LIFMIOR, povejte zdravniku, če imate ali ste kdaj imeli limfom (vrsta krvnega raka) ali drugo obliko raka.
Serious infections, sepsis, tuberculosis, and opportunistic infections, including invasive fungal infections, listeriosis and legionellosis, have been reported with the use of LIFMIOR (see section 4.8). 
Pri uporabi zdravila LIFMIOR so poročali o primerih resnih okužb, sepse, tuberkuloze in oportunističnih okužb, vključno z invazivnimi glivičnimi okužbami, listeriozo in legionelozo (glejte poglavje 4.8).
The results are shown in the figure below. 
Izsledki so predstavljeni na spodnji sliki.